{
    "clinical_study": {
        "@rank": "163139", 
        "arm_group": [
            {
                "arm_group_label": "Low-dose group", 
                "arm_group_type": "Experimental", 
                "description": "Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days"
            }, 
            {
                "arm_group_label": "Medium-dose group", 
                "arm_group_type": "Experimental", 
                "description": "Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days"
            }, 
            {
                "arm_group_label": "High-dose group", 
                "arm_group_type": "Experimental", 
                "description": "Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Active Comparator", 
                "description": "Edaravone Injection\uff0c30 mg/dose, one dose every 12 hours, continues for 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "1. To investigate the efficacy and safety of multi-doses Compound Edaravone Injection\n           versus Edaravone Injection for acute ischemic stroke patients;\n\n        2. To provide evidence for the design of Compound Edaravone Injection Phase III trial."
        }, 
        "brief_title": "Compound Edaravone Injection for Acute Ischemic Stroke", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hospitalized patients, diagnosed of ischemic stroke;\n\n          -  Onset of stroke is less than or equal to 48 hours;\n\n          -  There are clear signs of neurological deficit: 4\u2264NIHSS score\u226424, and also, the sum of\n             NIHSS score for the upper limb and the lower limb is greater than or equal to 2;\n\n          -  Patients signed written inform consent.\n\n        Exclusion Criteria:\n\n          -  Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural\n             hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid\n             hemorrhage;\n\n          -  Iatrogenic stroke;\n\n          -  Severe disturbance of consciousness: NIHSS category 1a for consciousness is greater\n             than 1\uff1b\n\n          -  The mRS score prior to this onset is greater than 1;\n\n          -  Transient ischemic attack (TIA);\n\n          -  SBP after blood pressure control is still greater than to equal to 220 mmHg, or DBP\n             after blood pressure control is still greater than or equal to 120 mmHg;\n\n          -  Patients with severe mental disorders and dementia;\n\n          -  ALT or AST is greater than 2.0\u00d7ULN or previously known liver diseases, such as acute\n             hepatitis, chronic active hepatitis, liver cirrhosis;\n\n          -  Creatinine clearance is less than 30 ml/min or previously known severe renal\n             diseases;\n\n          -  Therapeutic neuroprotective agents have been applied after onset, including\n             commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam,\n             butyl benzene peptides, Urinary Kallidinogenase;\n\n          -  Arterial or venous thrombolytic therapy has been applied after onset;\n\n          -  With malignant tumors or receiving concurrent antitumor treatment;\n\n          -  With severe systemic disease, life expectancy is less than 90 days;\n\n          -  Pregnant or lactating women;\n\n          -  Participate in other clinical studies within 30 days before randomization;\n\n          -  The investigators consider the patients are not suitable for this trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929096", 
            "org_study_id": "SIM-23-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low-dose group", 
                    "Medium-dose group", 
                    "High-dose group"
                ], 
                "intervention_name": "Compound Edaravone Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control group", 
                "intervention_name": "Edaravone Injection", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Phenylmethylpyrazolone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 22, 2013", 
        "location": {
            "contact": {
                "last_name": "Yongjun Wang, MD", 
                "phone": "86-010-67096611"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Beijing Tiantan Hospital affiliated to Capital Medical University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Multi-dose, Parallel, and Controlled Phase II Trial", 
        "overall_official": {
            "affiliation": "Beijing Tiantan Hospital", 
            "last_name": "Yongjun Wang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "mRS score on day 90", 
                "safety_issue": "No", 
                "time_frame": "day 90"
            }, 
            {
                "measure": "Change from baseline NIHSS score on day 14", 
                "safety_issue": "No", 
                "time_frame": "day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929096"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of patients with NIHSS score 0-1 (including motor function) on day 14, 30, 90", 
                "safety_issue": "No", 
                "time_frame": "day 14, 30, 90"
            }, 
            {
                "measure": "The proportion of patients with Barthel Index (BI) score greater than or equal to 95 on day 14, 30, 90", 
                "safety_issue": "No", 
                "time_frame": "day 14, 30, 90"
            }, 
            {
                "measure": "The Montreal Cognitive Assessment(MoCA) score on day 14, 30, 90", 
                "safety_issue": "No", 
                "time_frame": "day 14, 30, 90"
            }, 
            {
                "measure": "Stroke Impact Scale (SIS) score on day 90", 
                "safety_issue": "No", 
                "time_frame": "day 90"
            }
        ], 
        "source": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}